Probi is launching new probiotic iron absorption product and receives award nomination

Probi is now launching a new probiotic iron absorption product, Probi FerroSorb®. The product will be available through partners world-wide and the first market launch is planned for the beginning of 2016. Probi FerroSorb®has also been nominated to the Food Ingredients Europe Innovation Awards 2015, in the category ‘Best Functional Innovation’. The winner will be announced at the FiE event in Paris in December 2015.

Probi FerroSorb® offers a new approach for probiotic consumer products, both within functional food and consumer healthcare segments. First product launch is planned to take place in Sweden in February 2016, and other international markets are to follow for the rest of the year and in 2017.

“Probi is already very successful with Probi Digestis® and Probi Defendum®, our gastro and immune platforms. We are now very proud to launch the new probiotic platform Probi FerroSorb®, targeting iron deficiency in a unique way. This will create an opportunity for continuous growth for the probiotic category,” says Linda Neckmar, Director of Marketing & Sales Consumer Healthcare.

Well documented product with strong consumer benefits

Probi FerroSorb® is well documented through five clinical trials showing a significant increase of iron absorption from a meal. The consumer benefit of this groundbreaking R&D is an increased iron uptake while maintaining a well-functioning digestive system.

Probi FerroSorb® formulated into a capsule is a combination of the clinically documented lactic acid bacteria LP299V®, vitamin C, folic acid and a carefully balanced amount of iron. It is a supplement for preventive use targeting women of childbearing age at risk of iron deficiency. One capsule daily with the main meal will help to meet iron requirements, while leaving a minimal amount of unabsorbed iron in the intestines. Probi FerroSorb® solves iron deficiency in a completely new way, by increasing the uptake – not only the intake.

“The crucial difference between Probi FerroSorb® and a traditional iron supplement is the reduced risk of side effects normally seen with traditional iron supplement,” adds Linda Neckmar.

“We are very proud to have been nominated for this award, it is a proof that our R&D can bring new innovative products to the market addressing a widespread unmet medical need.” says Gun-Britt Fransson, Director of R&D.

World-wide nutritional disorder

According to the World Health Organization (WHO) iron deficiency is the predominant nutritional deficiency world-wide, both in industrialized and developing countries.  About 20-30% of the women in child bearing age suffer from iron deficiency with symptoms as fatigue, shortness of breath, poor immune function and impaired concentration.

The gastrointestinal side effects of traditional high dose iron supplements are often caused by poor absorption. Unabsorbed iron in the intestines can upset the intestinal flora and cause symptoms such as nausea and constipation. One of the reasons for these side effects is that iron acts as a nutrient for several undesirable intestinal bacteria. The conflict between a high iron requirement and the risk of side effects when using high doses of iron supplement can only be solved in one way – by improving the iron uptake.

FOR FURTHER INFORMATION, CONTACT:
Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se
Linda Neckmar, Director M&S, Consumer Healthcare, Probi, tel +46 46 286 89 71 or mobile +46 733 47 71 71, e-mail: linda.neckmar@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health- product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2014, Probi had sales of MSEK 135. The Probi share is listed on NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. Read more at www.probi.se 

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Media

Media

Documents & Links